GlassScriptPhysician profile
Amit M Patel
NPI 1346553120
$9,212.81
in general payments reported to CMS, 2019-2025
21 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $103 · 2021: $278 · 2022: $581 · 2023: $735 · 2024: $6,879 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,070 · Food and Beverage: $2,088 · Travel and Lodging: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,070.00 |
| Food and Beverage | $2,087.98 |
| Travel and Lodging | $883.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $6,175.25 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $760.78 | 2019-2025 | |
| Femselect INC. | $406.74 | 2023-2024 | Enplace |
| Regeneron Healthcare Solutions, INC. | $334.23 | 2020-2025 | Dupixent |
| Amgen INC. | $313.37 | 2020-2025 | Otezla, Otezla |
| Abbvie INC. | $211.59 | 2019-2024 | |
| Janssen Biotech, INC. | $190.40 | 2019-2023 | Tremfya, Remicade, Simponi |
| Incyte Corporation | $114.29 | 2022-2025 | Opzelura |
| Kerecis Limited | $110.76 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Arcutis Biotherapeutics, INC. | $92.29 | 2024 | Zoryve |
| Celgene Corporation | $82.97 | 2019-2024 | Sotyktu |
| Genzyme Corporation | $78.02 | 2020-2025 | |
| Shockwave Medical, INC | $74.85 | 2025 | |
| Lilly USA, LLC | $64.88 | 2019-2023 | Taltz |
| Allergan, INC. | $59.66 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.84 | 2022-2024 | Spevigo |
| Leo Pharma INC. | $21.60 | 2023 | Adbry |
| Astrazeneca Pharmaceuticals LP | $19.94 | 2022 | |
| Mayne Pharma Commercial LLC | $19.33 | 2019 | |
| Teleflex LLC | $18.65 | 2025 | Manta |
| Sun Pharmaceutical Industries INC. | $15.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.